Clinical trial • Phase I • Immunology
PF-07985631 for IgA nephropathy
Phase I trial of PF-07985631 for IgA nephropathy. 92 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- IgA nephropathy
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 15-05-2025
- First CTIS Authorization Date
- 01-07-2025
Trial design
Phase I trial across 1 site in Belgium.
- Target Sample Size
- 92
Eligibility
Recruits 92 Vulnerable population selected: true; no details on consent or assent handling provided in the record..
- Vulnerable Population
- Vulnerable population selected: true; no details on consent or assent handling provided in the record.
Recruitment
- Planned Sample Size
- 92
- Recruitment Window Months
- 15
Methods
- Site contact: Pfizer Clinical Research Unit, Route de Lennik 808, Brussels, Belgium; contact email PfizerVolRecruitment@pfizer.com; phone +3225567003; target population: Healthy volunteers (as listed)
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 92
Belgium
- Earliest CTIS Part Ii Submission Date
- 13-06-2025
- Latest Decision Or Authorization Date
- 25-09-2025
- Processing Time Days
- 104
- Number Of Sites
- 1
- Number Of Participants
- 92
Sites
- Site Name
- Pfizer Clinical Research Unit
- Contact Person Name
- Alexandre Stouffs
- Contact Person Email
- PfizerVolRecruitment@pfizer.com
Sponsor
Primary sponsor
- Full Name
- Pfizer Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- PF-07985631
Related trials
Other published trials that may interest you.